SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IPIC
IPIC 0.00010000.0%Aug 15 3:35 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Smarthayo who wrote (1158)4/3/1998 1:03:00 PM
From: margaret foley   of 1359
 
Yes, good news. Why fast track?

"The reason for Fast Track designation is to speed the
delivery of important new therapies to patients in need," Glenn
Cooper, Interneuron chief executive officer, said in a release.
Interneuron said the FDA decided CerAxon is intended to
treat a serious or life-threatening condition that currently
has an unmet medical need.
The "fast track" designation also means the FDA can take
actions to expedite the development and review of CerAxon, the
biopharmaceutical company said.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News